More Than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen(Oct 31, 2009)

Cork, Ireland (October 31, 2009) –Tibotec announced today results of a new study (VX950-C208), which showed that sustained virologic response (SVR) was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either every 8 hours or every 12 hours,  in combination with standard of care.  Telaprevir, an investigational STAT-C (pecifically argeted ntiviral herapy for hepatitis ), is being co-developed by Tibotec in collaboration with Vertex Pharmaceuticals.  The study was presented today at the 60 Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting).....